My take is that DeGrado’s association with brilacidin is a positive overall, but I don’t think he will have an impact in promoting brilacidin with Kessler or getting funding from the government. DeGrado's past relationship with Kessler would be a hinderance since Kessler holds a political position and he would want to keep his distance for fear of being accused of cronyism as was the case in the past administration. If the drug works in clinical trials I expect Kessler to give credit where credit is due. That’s some months or more in the future imo.
And I don't think DeGrado's name would mean anything to the gatekeepers at the hospitals set up to do a placebo-controlled clinical trial as IPIX plans to do.
DeGrado's name has the biggest impact among the investment community (the eternal optimists) for the reassurance it provides that the inventor has joined forces with the company developing the invention. The value of that would be much easier to judge if we knew what he was offered, or demanded, to join.
All my opinions, of course.
News 
Market Data 
Discover 
